医学部 内科学(ばんたね病院)

yoshinaga masataka

  (良永 真隆)

Profile Information

Affiliation
Fujita Health University

J-GLOBAL ID
201501015900620652
researchmap Member ID
7000012728

Research Areas

 1

Research History

 1

Papers

 14
  • Masataka Yoshinaga, Takashi Muramatsu, Masato Ishikawa, Takuo Toriya, Takashi Uwatoko, Yuji Matsuwaki, Yuko Ukai, Yohei Kobayashi, Katsuyoshi Ito, Hideaki Ota, Hideo Izawa
    Cardiovascular intervention and therapeutics, Aug 13, 2024  
    Slow-flow or no-reflow phenomenon is a common procedural complication during percutaneous coronary intervention (PCI). Given the presence of fragile plaque or thrombotic materials, we hypothesized that long-time predilatation using a perfusion balloon in conjunction with intracoronary nicorandil administration reduces the risk of slow-flow or no-reflow in patients presenting with acute coronary syndrome (ACS). Subjects were patients presenting with ACS who underwent PCI between April 2020 and April 2022. We retrospectively investigated the incidence of slow-flow or no-reflow during the procedure as well as in-hospital outcomes in comparison between the cases undergoing 3-min predilatation using a perfusion balloon in conjunction with intracoronary nicorandil administration followed by DES implantation (PB group) and those with direct stenting (DS group). Among 439 ACS patients, 36 patients in the PB group and 51 patients in the DS group were examined. Mean age was 70 years and 78.2% was male. Distal protection devices were more frequently used in the DS group than in the PB group (31.3% vs. 11.1%, p = 0.02). The incidence rate of slow-flow or no-reflow was significantly lower in the PB group than in the DS group (2.8% vs. 23.5%; p < 0.01). Six cases (11.7%) in the DS group required intra-aortic balloon pumping (IABP), while none in the PB group required (p < 0.01). In-hospital clinical outcomes did not differ between the two groups. Prolonged perfusion balloon predilatation in conjunction with intracoronary nicorandil administration was safe and feasible. This novel strategy could be an attractive alternative to conventional direct stenting for ACS patients.
  • Yuji Matsuwaki, Takashi Muramatsu, Yukio Ozaki, Takashi Uwatoko, Takuo Toriya, Hidemaro Takatsu, Yu Yoshiki, Masataka Yoshinaga, Masato Ishikawa, Masaya Ohota, Hideaki Ota, Hideo Izawa
    Fujita medical journal, 10(1) 16-23, Feb, 2024  
    OBJECTIVE: To examine the clinical outcomes of optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI) in patients presenting with ST-segment elevation myocardial infarction (STEMI). METHODS: We retrospectively investigated 533 consecutive patients who underwent primary PCI for STEMI between June 2016 and December 2020. The primary endpoint was a target lesion failure (TLF; defined as a composite of cardiac death, target vessel myocardial infarction, or target lesion revascularization). Propensity score (PS) matching was performed to allow direct comparison of OCT-guided and intravascular ultrasound (IVUS)-guided PCI. RESULTS: Patients in the OCT group (n=166) were younger than those in the IVUS group (n=367) and had a significantly higher left ventricular ejection fraction and estimated glomerular filtration rate. Killip class IV and left main stem disease were more common in the IVUS group. The median peak creatine kinase level was comparable between the two groups (1953 U/L vs 1603 U/L). A significantly larger amount of contrast was used in the OCT group (200 mL vs 165 mL; p<0.001). The cumulative incidence of TLF during a median follow-up of 2.2 years did not differ significantly between OCT and IVUS groups (9.6% vs 13.6%; p=0.221) but cardiac mortality was significantly higher in the IVUS group (8.7% vs 3.6%; p=0.047). After PS matching (n=161 in each group), there was no significant between-group difference in TLF or any other clinical outcome measures. CONCLUSIONS: OCT-guided PCI demonstrated clinical outcomes in patients with STEMI that were comparable to those of IVUS-guided PCI despite considerable differences in background characteristics.
  • Masataka Yoshinaga, Takashi Muramatsu, Hidetsugu Fujigaki, Kuniaki Saito, Hideo Izawa
    Fujita medical journal, 8(2) 65-66, May, 2022  
  • Yuji Kono, Hideo Izawa, Yoichiro Aoyagi, Ryo Yamada, Tomoya Ishiguro, Masataka Yoshinaga, Satoshi Okumura, Wakaya Fujiwara, Mutsuharu Hayashi, Yohei Otaka
    Heart and vessels, 36(12) 1856-1860, Dec, 2021  
    The study aimed to identify factors related to bone mineral density (BMD) among older patients with heart failure (HF). A total of 70 consecutive patients with HF aged 65 years or older who were admitted to an acute hospital due to worsening condition were enrolled before discharge. BMD of the femoral neck was evaluated using the DEXA method. Physical function, as well as echocardiographic and laboratory findings including biomarker of HF severity were collected. Bivariate and multiple regression analyses were employed to determine the association between BMD and the clinical variables. Bivariate analysis determined that age, grip strength, walking speed, serum albumin, and N-terminal pro B-type natriuretic peptide (NT-proBNP) were significantly correlated with BMD (P < 0.01), whereas other clinical parameters were not. The multiple regression analysis identified NT-proBNP as an independent related factor for BMD after adjusting with confounding clinical variables. NT-proBNP was independently related to BMD among older patients with HF. Our results suggest the inclusion of bone fracture prevention strategies in disease management programs, especially for older patients with HF.
  • Ueda Sayano, Kono Yuji, Yamada Ryo, Ishiguro Tomoya, Yoshinaga Masataka, Okumura Satoshi, Fujiwara Wakaya, Hayashi Mutsuharu, Aoyagi Yoichiro, Saitoh Eiichi, Otaka Yohei, Izawa Hideo
    Fujita Medical Journal, 7(2) 65-69, May, 2021  
    BACKGROUND: Anaerobic threshold (AT) during cardiopulmonary exercise testing (CPET) is not always determinable in patients with heart failure (HF). However, little is known about the clinical features of patients with HF who have indeterminable AT. Therefore, the present study aimed to clarify the clinical features of such patients. METHODS: A total of 70 patients with HF (58 males; age: 68±12 years) who underwent CPET during hospitalization were divided into two groups: determinable AT (n=50) and indeterminable AT (n=20). Physical function, echocardiographic results, and laboratory findings were subsequently determined. RESULTS: Univariate analyses showed that the indeterminable AT group had significantly higher age and left ventricular ejection fraction, and significantly lower body mass index, calf circumference, handgrip strength, walking speed, serum hemoglobin, and serum albumin than the determinable AT group. Multiple logistic regression analysis identified handgrip strength and walking speed as independent predictive factors for indeterminable AT. Receiver-operating characteristic analyses revealed that handgrip strength of 21.2 kg and walking speed of 0.97 m/s were optimal cutoff values for differentiating patients who were likely to experience indeterminable AT. CONCLUSIONS: The present study identified handgrip strength and walking speed as powerful predictors for indeterminable AT with HF.

Misc.

 44
  • Masataka Yoshinaga, Takashi Muramatsu, Hidetsugu Fujigaki, Kuniaki Saito, Hideo Izawa
    Fujita medical journal, 8(2) 65-66, May, 2022  
  • 松脇 佑次, 小林 昌義, 丹羽 若菜, 良永 真隆, 村松 崇, 井澤 英夫
    脈管学, 61(Suppl.) S247-S247, Oct, 2021  
  • 大田将也, 尾崎行男, 鳥谷卓夫, 鷹津英麿, 長坂遼, 吉木優, 橋本洋輔, 石川正人, 良永正隆, 河合秀樹, 村松崇, 成瀬寛之, 井澤英夫
    日本循環器学会学術集会(Web), 85th, 2021  
  • Tomoya Ishiguro, Mutsuharu Hayashi, Wakaya Fujiwara, Satoshi Okumura, Masataka Yoshinaga, Ryo Yamada, Sayano Ueda, Takehiro Ito, Yudai Niwa, Akane Miyazaki, Masahide Harada, Hiroyuki Naruse, Junnichi Ishii, Yukio Ozaki, Hideo Izawa
    Fujita medical journal, 7(1) 18-22, 2021  
    OBJECTIVES: MicroRNAs (miRNA) are functional RNAs that have emerged as pivotal gene expression regulators in cardiac disease. Although several cardiomyocyte miRNAs have been reported to play roles in heart failure progression among patients with idiopathic dilated cardiomyopathy (DCM), the role of circulating miRNAs has not yet been well-examined. METHODS: After total RNA extraction from the peripheral blood samples of three control participants and six patients with DCM, miRNA profiling was performed using miRNA arrays. Based on the results of this initial screening, real-time polymerase chain reaction (RT-PCR) was used to perform a quantitative analysis of blood samples from a larger number of matched patients (DCM, n=20; controls, n=5). Finally, the correlations between specific miRNA expression levels and hemodynamic parameters were analyzed. RESULTS: A primary screening of 2,565 miRNAs resulted in the identification of nine miRNA candidates. Quantitative RT-PCR results revealed significantly increased miR-489 expression levels in the DCM group. Moreover, there was a significant positive correlation between miR-489 expression level and left ventricular ejection fraction. CONCLUSIONS: Our results suggest that circulating miR-489 could be a potential noninvasive diagnostic biomarker for DCM. Additionally, the quantification of circulating miR-489 may have value as a potential prognostic marker for patients with DCM.
  • Ryo Yamada, Satoshi Okumura, Yuji Kono, Akane Miyazaki, Yudai Niwa, Takehiro Ito, Sayano Ueda, Tomoya Ishiguro, Masataka Yoshinaga, Wakaya Fujiwara, Mutsuharu Hayashi, Yukio Ozaki, Eiichi Saitoh, Hideo Izawa
    Fujita medical journal, 7(3) 76-82, 2021  
    OBJECTIVES: There are benefits of exercise-based cardiac rehabilitation (CR) in patients with heart failure (HF), but their underlying molecular mechanisms remain elusive. The effect of CR on the expression profile of circulating microRNAs (miRNAs), which are short noncoding RNAs that regulate posttranscriptional expression of target genes, is unknown. If miRNAs respond to changes following CR for HF, then serum profiling of miRNAs may reveal cardioprotective mechanisms of CR. METHODS: This study enrolled three hospitalized patients with progressed systolic HF and three normal volunteer controls. In patients, CR was initiated after improvement of HF, which included 2 weeks of bicycle ergometer and resistance exercises. Genome-wide expression profiling of circulating miRNAs was performed using microarrays for the patients (mean±SD age, 60.0±12.2 years) and controls (58.7±0.58 years). Circulating miRNA expression profiles were compared between patients with HF before and after CR and the controls. RESULTS: Expression levels of two miRNAs were significantly different in patients before CR compared with controls and patients after CR. The expression of hsa-miR-125b-1-3p was significantly downregulated and that of hsa-miR-1290 was significantly upregulated in patients before CR. CONCLUSIONS: When performing CR, expression of certain circulating miRNAs in patients with HF is restored to nonpathological levels. The benefits of CR for HF may result from regulation of miRNAs through multiple effects of gene expression.

Presentations

 9